Whether your drug is in an early development phase or in the lifecycle management phase, it is important to know when and how to invest in Medical Affairs. In their discussion this month, Peg and John Yee, MD, MPH and former CMO at Sobi, focus on the value of and the critical need to invest in Medical Affairs. They see Medical Affairs as the “bridge” across all functions and that it sits at the intersection of medicine, science, and business. They highlight the need to communicate and engage with the commercial side of the organization while building a Medical Affairs team and Dr. Yee describes how each team member should be a “triple threat” in the areas of scientific excellence, business acumen, and emotional intelligence. He provides first-hand experience and advice on all of these topics, and we believe that CMOs will find a wealth of Medical Affairs knowledge in this podcast.